These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 31289948)

  • 21. The pros and cons of a single 'Euro-price' for drugs.
    Towse A
    Pharmacoeconomics; 1998 Mar; 13(3):271-6. PubMed ID: 10178652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of external price referencing of pharmaceuticals in Middle East countries.
    Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-national drug price comparisons with economic weights in external reference pricing in Germany.
    Mahlich J; Sindern J; Suppliet M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):37-43. PubMed ID: 30273062
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of reference pricing in pharmaceutical markets: a review.
    Galizzi MM; Ghislandi S; Miraldo M
    Pharmacoeconomics; 2011 Jan; 29(1):17-33. PubMed ID: 21142276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications.
    Incze A; Kaló Z; Espín J; Kiss É; Kessabi S; Garrison LP
    Front Pharmacol; 2022; 13():815029. PubMed ID: 35462921
    [No Abstract]   [Full Text] [Related]  

  • 27. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug price transparency initiative: A scoping review.
    Ahmad NS; Makmor-Bakry M; Hatah E
    Res Social Adm Pharm; 2020 Oct; 16(10):1359-1369. PubMed ID: 31987771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare.
    Critchley GJ; Zaric GS
    Health Econ; 2019 Aug; 28(8):1035-1051. PubMed ID: 31310424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. International trade and determinants of price differentials of insulin medicine.
    Helble M; Aizawa T
    Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model.
    Riccaboni M; Swoboda T; Van Dyck W
    Health Policy; 2022 Jun; 126(6):534-540. PubMed ID: 35459584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in external price referencing in Europe: a descriptive overview.
    Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
    Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries.
    Kang SY; DiStefano MJ; Socal MP; Anderson GF
    Health Aff (Millwood); 2019 May; 38(5):804-811. PubMed ID: 31059372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues.
    Danzon PM
    Pharmacoeconomics; 2018 Dec; 36(12):1395-1405. PubMed ID: 30062518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comment on the implications of external price referencing of pharmaceuticals in Middle East countries.
    Carapinha JL
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):11-4. PubMed ID: 26707161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.